Post by
rgonlyfactspls on Nov 01, 2015 11:51am
Annual gross margin of global top 25 pharmas in 2014
Several big name pharmas with a strategic focus on cancer treatments and oncology in particular, are below the "AVERAGE" gross margin level of these 25 pharmas that made the list. Surely Telesta, with MCNA at a margin level of 90-95%, will be like a drug they must have (once/if MCNA approved by FDA). How could they tell their shareholders they did not seriously consider acquiring Telesta???...unless Tele$ta becomes too pricey very quickly. GLTA --- https://www.statista.com/statistics/473429/top-global-pharmaceutical-companies-gross-margin-values/ --- Also, see second link for additional info relating to large biotechs' gross margin levels in Q1-15 --- https://www.statista.com/statistics/274572/gross-profit-margin-of-united-states-biotech-companies/
Comment by
RetailRube on Nov 01, 2015 1:49pm
90-95% gross margin sounds quite high considering we have to pay Endo a 5% royalty on global revenue. Margin will be high, but I will believe it when the company discloses it in writing, or I can analyse the actual results when they have revenue. Which could be soon.
Comment by
RetailRube on Nov 01, 2015 1:53pm
Nonetheless, RGFacts, I rated your post a 5. Thanks for contacting the analyst and letting us know what he said.
Comment by
cheetio on Nov 02, 2015 12:55pm
Does anyone think that this management team would split 15:1 before ADComm meeting........ha.......watch and see
Comment by
DryBones on Nov 02, 2015 4:22pm
Punter. If I was management at TST, I would llft a finger to getting mcna approved in Endo's market area: Canada, South Africa and Mexico. Let Endo come back to the table and beg.
Comment by
txbioinv on Nov 02, 2015 4:49pm
Punter, thanks for confirming the 10 years, much appreciated. I still believe old bioniche leadership and old endo leadership were 'on the same page' if you know what I mean....................GL longtimers